{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:42:01Z","timestamp":1786470121268,"version":"build-2736575974"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40262-026-01668-8","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:07:51Z","timestamp":1783444071000},"page":"1115-1130","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Physiologically Based Pharmacokinetic (PBPK) Modeling of Antidepressants: A Scoping Review of Existing Models, Applications, and Software Tools"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0302-3925","authenticated-orcid":false,"given":"Rebecca Leyla","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9231","authenticated-orcid":false,"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"1668_CR1","unstructured":"World Health Organization. Depressive disorder (depression). Fact sheets. 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression. Accessed 27 Dec 2025."},{"issue":"1","key":"1668_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62381-9","volume":"14","author":"J Liu","year":"2019","unstructured":"Liu J, Liu Y, Ma W, Tong Y, Zheng J. Temporal and spatial trend analysis of all-cause depression burden based on Global Burden of Disease (GBD) 2019 study. Sci Rep. 2019;14(1):12346.","journal-title":"Sci Rep"},{"issue":"1","key":"1668_CR3","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12888-025-06932-y","volume":"25","author":"Y Fan","year":"2025","unstructured":"Fan Y, Fan A, Yang Z, Fan D. Global burden of mental disorders in 204 countries and territories, 1990\u20132021: results from the global burden of disease study 2021. BMC Psychiatry. 2025;25(1):486.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1668_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/wps.20941","volume":"21","author":"F Leichsenring","year":"2022","unstructured":"Leichsenring F, Steinert C, Rabung S, Ioannidis JPA. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. World Psychiatry. 2022;21(1):133\u201345.","journal-title":"World Psychiatry"},{"issue":"9","key":"1668_CR5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.mayocp.2015.06.016","volume":"90","author":"M Zimmerman","year":"2015","unstructured":"Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Have treatment studies of depression become even less generalizable? A review of the inclusion and exclusion criteria used in placebo-controlled antidepressant efficacy trials published during the past 20 years. Mayo Clin Proc. 2015;90(9):1180\u20136.","journal-title":"Mayo Clin Proc"},{"key":"1668_CR6","doi-asserted-by":"crossref","unstructured":"McDonagh M, Matthews A, Phillipi C, Romm J, Peterson K, Thakurta S, Guise J-M. Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence Report\/Technology Assessment No. 216. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2007-10057-I.). AHRQ Publication No. 14-E003-EF. Rockville (MD): Agency for Healthcare Research and Quality; July 2014.","DOI":"10.23970\/AHRQEPCERTA216"},{"key":"1668_CR7","unstructured":"Sobieraj DM, Baker WL, Martinez BK, Hernandez AV, Coleman CI, Ross JS, et al. Adverse effects of pharmacologic treatments of major depression in older adults. Comparative Effectiveness Review No. 215. (Prepared by the University of Connecticut Evidence-based Practice Center under Contract No. 290-2015-00012-I.). AHRQ Publication No. 19-EHC011-EF. Rockville (MD): Agency for Healthcare Research and Quality; March 2019."},{"key":"1668_CR8","doi-asserted-by":"crossref","unstructured":"Perry C, Davis G, Conner TM, Zhang T. Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: an overview. Curr Pharmacol Rep. 2020;6(3):71-84.","DOI":"10.1007\/s40495-020-00212-x"},{"key":"1668_CR9","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.2147\/DDDT.S501143","volume":"19","author":"X Wu","year":"2025","unstructured":"Wu X, Wang Z, Liu S, Wang H. Utilizing physiologically based pharmacokinetic models to support rational medication in Chinese elderly population. Drug Des Devel Ther. 2025;19:3077\u2013101.","journal-title":"Drug Des Devel Ther."},{"issue":"12","key":"1668_CR10","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s40262-025-01574-5","volume":"64","author":"LH Preta","year":"2025","unstructured":"Preta LH, Bouazza N, Foissac F, Froelicher L, Urien S, Buth V, et al. Prediction of maternal and fetal exposure to escitalopram, sertraline, and paroxetine by combining human ex vivo placenta perfusion data and physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2025;64(12):1843\u201354.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1668_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/psp4.12411","volume":"8","author":"F Storelli","year":"2019","unstructured":"Storelli F, Desmeules J, Daali Y. Physiologically-based pharmacokinetic modeling for the prediction of CYP2D6-mediated gene-drug-drug interactions. CPT Pharmacometrics Syst Pharmacol. 2019;8(8):567\u201376.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"1668_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40262-013-0056-7","volume":"52","author":"M Siccardi","year":"2013","unstructured":"Siccardi M, Marzolini C, Seden K, Almond L, Kirov A, Khoo S, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013;52(7):583\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"1668_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004495","volume":"12","author":"J Lu","year":"2016","unstructured":"Lu J, Goldsmith M-R, Grulke CM, Chang DT, Brooks RD, Leonard JA, et al. Developing a physiologically-based pharmacokinetic modelkKnowledgebase in support of provisional model construction. PLoS Comput Biol. 2016;12(2):e1004495.","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"1668_CR14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1002\/bcp.70084","volume":"91","author":"M Scherf-Clavel","year":"2025","unstructured":"Scherf-Clavel M, Leutritz AL, Gehrmann A, Unterecker S, Walther S, Kittel-Schneider S. Physiologically based pharmacokinetic modelling predicts altered maternal pharmacokinetics of amitriptyline during pregnancy. Br J Clin Pharmacol. 2025;91(9):2636\u201348.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1668_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.xphs.2017.11.012","volume":"107","author":"Z Tylutki","year":"2018","unstructured":"Tylutki Z, Mendyk A, Polak S. Mechanistic physiologically based pharmacokinetic (PBPK) model of the heart accounting for inter-individual variability: development and performance verification. J Pharm Sci. 2018;107(4):1167\u201377.","journal-title":"J Pharm Sci"},{"issue":"5","key":"1668_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s10928-018-9597-6","volume":"45","author":"Z Tylutki","year":"2018","unstructured":"Tylutki Z, Mendyk A, Polak S. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals. J Pharmacokinet Pharmacodyn. 2018;45(5):663\u201377.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1668_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep39494","volume":"7","author":"Z Tylutki","year":"2017","unstructured":"Tylutki Z, Polak S. A four-compartment PBPK heart model accounting for cardiac metabolism: model development and application. Sci Rep. 2017;7:39494.","journal-title":"Sci Rep"},{"issue":"1","key":"1668_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1515\/bams-2015-0043","volume":"12","author":"Z Tylutki","year":"2016","unstructured":"Tylutki Z, Jornil J, Polak S. The effect of increasing amitriptyline doses on cardiomyocytes\u2019 electrophysiology: simulation study. Bio-Algorithms and Med-Systems. 2016;12(1):33\u20138.","journal-title":"Bio-Algorithms and Med-Systems"},{"issue":"8","key":"1668_CR19","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1002\/jps.22115","volume":"99","author":"BA Howell","year":"2010","unstructured":"Howell BA, Chauhan A. A physiologically based pharmacokinetic (PBPK) model for predicting the efficacy of drug overdose treatment with liposomes in man. J Pharm Sci. 2010;99(8):3601\u201319.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1668_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020179","volume":"17","author":"UR Luecht","year":"2025","unstructured":"Luecht UR, Scholz W, Geiben AK, Haen E, Hempel G. Physiologically based pharmacokinetic model of CYP2D6 associated interaction between venlafaxine and strong inhibitor bupropion: the influence of age-relevant changes and inhibitory dose to classify therapeutical success and harm. Pharmaceutics. 2025;17(2):179.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1668_CR21","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1002\/cpt.3604","volume":"117","author":"S Rudesheim","year":"2025","unstructured":"Rudesheim S, Loer HLH, Feick D, Marok FZ, Fuhr LM, Selzer D, et al. A comprehensive CYP2D6 drug-drug-gene interaction network for application in precision dosing and drug development. Clin Pharmacol Ther. 2025;117(6):1718\u201331.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1668_CR22","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/bdd.2335","volume":"43","author":"T Zhang","year":"2022","unstructured":"Zhang T, Zou P, Fang Y, Li Y. Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk. Biopharm Drug Dispos. 2022;43(6):221\u201332.","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"1668_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10928-021-09778-5","volume":"48","author":"NH Hsieh","year":"2021","unstructured":"Hsieh NH, Bois FY, Tsakalozou E, Ni Z, Yoon M, Sun W, et al. A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms. J Pharmacokinet Pharmacodyn. 2021;48(6):893\u2013908.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1668_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030331","volume":"13","author":"FZ Marok","year":"2021","unstructured":"Marok FZ, Fuhr LM, Hanke N, Selzer D, Lehr T. Physiologically based pharmacokinetic modeling of bupropion and its metabolites in a CYP2B6 drug-drug-gene interaction network. Pharmaceutics. 2021;13(3):331.","journal-title":"Pharmaceutics"},{"key":"1668_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10010001","author":"C Xue","year":"2017","unstructured":"Xue C, Zhang X, Cai W. Prediction of drug-drug interactions with bupropion and its metabolites as CYP2D6 inhibitors using a physiologically-based pharmacokinetic model. Pharmaceutics. 2017. https:\/\/doi.org\/10.3390\/pharmaceutics10010001.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1668_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","volume":"52","author":"ZE Barter","year":"2013","unstructured":"Barter ZE, Tucker GT, Rowland-Yeo K. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2013;52(12):1085\u2013100.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1668_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/jcph.1541","volume":"60","author":"X Wu","year":"2020","unstructured":"Wu X, Zhang H, Miah MK, Caritis SN, Venkataramanan R. Physiologically based pharmacokinetic approach can successfully predict pharmacokinetics of citalopram in different patient populations. J Clin Pharmacol. 2020;60(4):477\u201388.","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"1668_CR28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2174\/0113892002270594231212090958","volume":"24","author":"V Uchaipichat","year":"2023","unstructured":"Uchaipichat V. Inhibitory effects of tricyclic antidepressants on human liver microsomal morphine glucuronidation: application of IVIVE to predict potential drug-drug interactions in humans. Curr Drug Metab. 2023;24(12):835\u201343.","journal-title":"Curr Drug Metab"},{"issue":"5","key":"1668_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051544","volume":"15","author":"GV Carapeto","year":"2023","unstructured":"Carapeto GV, Duque MD, Issa MG, Ferraz HG. Development of biopredictive dissolution method for extended-release desvenlafaxine tablets. Pharmaceutics. 2023;15(5):1544.","journal-title":"Pharmaceutics"},{"key":"1668_CR30","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ejps.2015.06.012","volume":"77","author":"F Franek","year":"2015","unstructured":"Franek F, Jarlfors A, Larsen F, Holm P, Steffansen B. In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation. Eur J Pharm Sci. 2015;77:303\u201313.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1668_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40780-021-00189-9","volume":"7","author":"K Adachi","year":"2021","unstructured":"Adachi K, Beppu S, Nishiyama K, Shimizu M, Yamazaki H. Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital. J Pharm Health Care Sci (Tokyo). 2021;7(1):6.","journal-title":"J Pharm Health Care Sci (Tokyo)"},{"issue":"5","key":"1668_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1124\/dmd.111.043554","volume":"40","author":"W Kielbasa","year":"2012","unstructured":"Kielbasa W, Stratford RE Jr. Exploratory translational modeling approach in drug development to predict human brain pharmacokinetics and pharmacologically relevant clinical doses. Drug Metab Dispos. 2012;40(5):877\u201383.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"1668_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17101341","volume":"17","author":"SY Choi","year":"2025","unstructured":"Choi SY, Yang E, Shin KH. Escitalopram dose optimization during pregnancy: a PBPK modeling approach. Pharmaceutics. 2025;17(10):1341.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1668_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cpt.3537","volume":"117","author":"YJ Jang","year":"2025","unstructured":"Jang YJ, Kim DK, Lim SW, Hong E. Impact of CYP2C19 phenotype on escitalopram response in geriatrics: based on physiologically-based pharmacokinetic modeling and clinical observation. Clin Pharmacol Ther. 2025;117(3):826\u201335.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1668_CR35","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1002\/jcph.70093","volume":"65","author":"R Kayesh","year":"2025","unstructured":"Kayesh R, Pressly M, Guinn D, Lin Z, Schmidt S, Fairman K, et al. Application of lactation physiologically based pharmacokinetic modeling to predict milk exposure of passively diffused drugs. J Clin Pharmacol. 2025;65(12):1637\u201349.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1668_CR36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/17425255.2023.2221847","volume":"19","author":"E Cardoso","year":"2023","unstructured":"Cardoso E, Guidi M, Nauwelaerts N, Nordeng H, Teil M, Allegaert K, et al. Safety of medicines during breastfeeding: from case report to modeling: a contribution from the ConcePTION project. Expert Opin Drug Metab Toxicol. 2023;19(5):269\u201383.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"12","key":"1668_CR37","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s40262-018-0657-2","volume":"57","author":"SR Delaney","year":"2018","unstructured":"Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Predicting escitalopram exposure to breastfeeding infants: integrating analytical and in silico techniques. Clin Pharmacokinet. 2018;57(12):1603\u201311.","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"1668_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40262-022-01123-4","volume":"61","author":"ME Willemin","year":"2022","unstructured":"Willemin ME, Zannikos P, Mannens G, de Zwart L, Snoeys J. Prediction of drug-drug interactions after esketamine intranasal administration using a physiologically based pharmacokinetic model. Clin Pharmacokinet. 2022;61(8):1115\u201328.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1668_CR39","first-page":"49","volume":"43","author":"M Spaenig","year":"2026","unstructured":"Spaenig M, Vogel M, Hansen T, Elenschneider L, Londenberg A, Whomsley R, et al. Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling. Altex. 2026;43(1):49\u201364.","journal-title":"Altex"},{"issue":"5","key":"1668_CR40","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/bdd.2334","volume":"43","author":"A Pansari","year":"2022","unstructured":"Pansari A, Faisal M, Jamei M, Abduljalil K. Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model. Biopharm Drug Dispos. 2022;43(5):201\u201312.","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"1668_CR41","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/jcph.1927","volume":"61","author":"HC Jeong","year":"2021","unstructured":"Jeong HC, Chae YJ, Lee S, Kang W, Yun HY, Shin KH. Prediction of fluoxetine and norfluoxetine pharmacokinetic profiles using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2021;61(11):1505\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1668_CR42","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/clpt.2014.50","volume":"95","author":"JE Sager","year":"2014","unstructured":"Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1668_CR43","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3390\/pharmaceutics15061586","volume":"15","author":"L Marques","year":"2023","unstructured":"Marques L, Vale N. Prediction of CYP-mediated drug interaction using physiologically based pharmacokinetic modeling: a case study of salbutamol and fluvoxamine. Pharmaceutics. 2023;15(6):1586.","journal-title":"Pharmaceutics"},{"issue":"12","key":"1668_CR44","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3390\/metabo12121281","volume":"12","author":"K Burhanuddin","year":"2022","unstructured":"Burhanuddin K, Badhan R. Optimising fluvoxamine maternal\/fetal exposure during gestation: a parmacokinetic virtual clinical trials study. Metabolites. 2022;12(12):1281.","journal-title":"Metabolites"},{"issue":"12","key":"1668_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/pharmaceutics12121191","volume":"12","author":"T Kanacher","year":"2020","unstructured":"Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JDG, et al. A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug-drug-gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol, and caffeine. Pharmaceutics. 2020;12(12):1191.","journal-title":"Pharmaceutics"},{"issue":"5","key":"1668_CR46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/psp4.12397","volume":"8","author":"H Britz","year":"2019","unstructured":"Britz H, Hanke N, Volz AK, Spigset O, Schwab M, Eissing T, et al. Physiologically-based pharmacokinetic models for CYP1A2 drug-drug interaction prediction: a modeling network of fluvoxamine, theophylline, caffeine, rifampicin, and midazolam. CPT Pharmacometrics Syst Pharmacol. 2019;8(5):296\u2013307.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1668_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.placenta.2017.08.010","volume":"58","author":"S Matsuoka","year":"2017","unstructured":"Matsuoka S, Hori S, Satoh H, Nagamatsu T, Fujii T, Sawada Y. Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. Placenta. 2017;58:74\u201381.","journal-title":"Placenta"},{"issue":"8","key":"1668_CR48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40262-016-0367-6","volume":"55","author":"S Alqahtani","year":"2016","unstructured":"Alqahtani S, Kaddoumi A. Development of a physiologically based pharmacokinetic\/pharmacodynamic model to predict the impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics represented by receptor\/transporter occupancy of central nervous system drugs. Clin Pharmacokinet. 2016;55(8):957\u201369.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1668_CR49","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jps.24320","volume":"104","author":"K Iga","year":"2015","unstructured":"Iga K. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. J Pharm Sci. 2015;104(4):1478\u201391.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1668_CR50","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s11095-007-9390-5","volume":"25","author":"M Geldof","year":"2008","unstructured":"Geldof M, Freijer J, van Beijsterveldt L, Danhof M. Pharmacokinetic modeling of non-linear brain distribution of fluvoxamine in the rat. Pharm Res. 2008;25(4):792\u2013804.","journal-title":"Pharm Res"},{"issue":"3","key":"1668_CR51","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s11095-023-03484-2","volume":"40","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM. Physiologically based pharmacokinetic model of brain delivery of plasma protein bound drugs. Pharm Res. 2023;40(3):661\u201374.","journal-title":"Pharm Res"},{"issue":"3","key":"1668_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejps.2011.08.003","volume":"44","author":"J Jornil","year":"2011","unstructured":"Jornil J, Jensen KG, Larsen F, Linnet K. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci. 2011;44(3):265\u201372.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"1668_CR53","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/pharmaceutics14081734","volume":"14","author":"S Rudesheim","year":"2022","unstructured":"Rudesheim S, Selzer D, Murdter T, Igel S, Kerb R, Schwab M, et al. Physiologically based pharmacokinetic modeling to describe the CYP2D6 activity score-dependent metabolism of paroxetine, atomoxetine and risperidone. Pharmaceutics. 2022;14(8):1734.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1668_CR54","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10928-020-09711-2","volume":"47","author":"K Abduljalil","year":"2020","unstructured":"Abduljalil K, Pansari A, Jamei M. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy. J Pharmacokinet Pharmacodyn. 2020;47(4):361\u201383.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"8","key":"1668_CR55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1111\/jphp.13281","volume":"72","author":"A Almurjan","year":"2020","unstructured":"Almurjan A, Macfarlane H, Badhan RKS. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study. J Pharm Pharmacol. 2020;72(8):1049\u201360.","journal-title":"J Pharm Pharmacol"},{"issue":"12","key":"1668_CR56","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1124\/dmd.113.052332","volume":"41","author":"M Nagai","year":"2013","unstructured":"Nagai M, Ohtani H, Satoh H, Matsuoka S, Hori S, Fujii T, et al. Characterization of transplacental transfer of paroxetine in perfused human placenta: development of a pharmacokinetic model to evaluate tapered dosing. Drug Metab Dispos. 2013;41(12):2124\u201332.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1668_CR57","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/ecp.13.4","volume":"6","author":"KR Yeo","year":"2013","unstructured":"Yeo KR, Jamei M, Rostami-Hodjegan A. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol. 2013;6(2):143\u201357.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1668_CR58","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1124\/dmd.109.030551","volume":"38","author":"J Jornil","year":"2010","unstructured":"Jornil J, Jensen KG, Larsen F, Linnet K. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010;38(3):376\u201385.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"1668_CR59","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/bcp.15826","volume":"91","author":"D Lartey","year":"2025","unstructured":"Lartey D, Jateng D, Li M, Nguyen C, Crentsil V, Beitz J, et al. Quantification of sertraline maternal\/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model. Br J Clin Pharmacol. 2025;91(4):1003\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1668_CR60","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/pharmaceutics15051469","volume":"15","author":"N Nauwelaerts","year":"2023","unstructured":"Nauwelaerts N, Macente J, Deferm N, Bonan RH, Huang MC, Van Neste M, et al. Generic workflow to predict medicine concentrations in human milk using physiologically-based pharmacokinetic (PBPK) modelling: a contribution from the ConcePTION Project. Pharmaceutics. 2023;15(5):1469.","journal-title":"Pharmaceutics"},{"issue":"6","key":"1668_CR61","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/bdd.2278","volume":"42","author":"A Almurjan","year":"2021","unstructured":"Almurjan A, Macfarlane H, Badhan RKS. The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: a virtual clinical trial pharmacokinetics study. Biopharm Drug Dispos. 2021;42(6):252\u201362.","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"1668_CR62","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41540-020-00157-3","volume":"6","author":"B George","year":"2020","unstructured":"George B, Lumen A, Nguyen C, Wesley B, Wang J, Beitz J, et al. Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. NPJ Syst Biol Appl. 2020;6(1):36.","journal-title":"NPJ Syst Biol Appl."},{"issue":"10","key":"1668_CR63","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/psp4.12110","volume":"5","author":"IE Templeton","year":"2016","unstructured":"Templeton IE, Chen Y, Mao J, Lin J, Yu H, Peters S, et al. Quantitative prediction of drug-drug interactions involving inhibitory metabolites in drug development: how can physiologically based pharmacokinetic modeling help? CPT Pharmacometrics Syst Pharmacol. 2016;5(10):505\u201315.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1668_CR64","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/cts.13253","volume":"15","author":"L Oggianu","year":"2022","unstructured":"Oggianu L, Di Dato G, Mangano G, Rosignoli MT, McFeely S, Ke AB, et al. Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations. Clin Transl Sci. 2022;15(6):1417\u201329.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"1668_CR65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s10928-025-09969-4","volume":"52","author":"X Pan","year":"2025","unstructured":"Pan X, Rowland YK. Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine in lactation. J Pharmacokinet Pharmacodyn. 2025;52(2):22.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1668_CR66","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s12272-024-01495-0","volume":"47","author":"CK Cho","year":"2024","unstructured":"Cho CK, Kang P, Jang CG, Lee SY, Lee YJ, Bae JW, et al. PBPK modeling to predict the pharmacokinetics of venlafaxine and its active metabolite in different CYP2D6 genotypes and drug-drug interactions with clarithromycin and paroxetine. Arch Pharm Res. 2024;47(5):481\u2013504.","journal-title":"Arch Pharm Res"},{"issue":"4","key":"1668_CR67","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s11095-024-03680-8","volume":"41","author":"C Shen","year":"2024","unstructured":"Shen C, Yang H, Shao W, Zheng L, Zhang W, Xie H, et al. Physiologically based pharmacokinetic modeling to unravel the drug-gene interactions of venlafaxine: based on activity score-dependent metabolism by CYP2D6 and CYP2C19 polymorphisms. Pharm Res. 2024;41(4):731\u201349.","journal-title":"Pharm Res"},{"issue":"2","key":"1668_CR68","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jpp\/rgad106","volume":"76","author":"M Alenezi","year":"2024","unstructured":"Alenezi M, Badhan RKS. Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach. J Pharm Pharmacol. 2024;76(2):122\u201337.","journal-title":"J Pharm Pharmacol"},{"issue":"10","key":"1668_CR69","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1016\/j.xphs.2016.06.015","volume":"105","author":"HP Lin","year":"2016","unstructured":"Lin HP, Sun D, Zhang X, Wen H. Physiologically based pharmacokinetic modeling for substitutability analysis of venlafaxine hydrochloride extended-release formulations using different release mechanisms: osmotic pump versus openable matrix. J Pharm Sci. 2016;105(10):3088\u201396.","journal-title":"J Pharm Sci"},{"key":"1668_CR70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2193-9616-1-9","volume":"1","author":"SM Masoud Jamei","year":"2013","unstructured":"Masoud Jamei SM, Edwards D, Wragg K, Feng K, Barnett A, Rostami-Hodjegan A. The Simcyp Population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol. 2013;1:9.","journal-title":"In Silico Pharmacol."},{"issue":"12","key":"1668_CR71","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/psp4.12473","volume":"8","author":"J Lippert","year":"2019","unstructured":"Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, et al. Open systems pharmacology community: an open access, open source, open science approach to modeling and simulation in pharmaceutical sciences. CPT Pharmacometrics Syst Pharmacol. 2019;8(12):878\u201382.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1668_CR72","doi-asserted-by":"crossref","unstructured":"Almajidi YQ, Faisal RR, Yaseen A, al-hakeem Mal. GastroPlus\u00ae as simulating\/ conducting software for modeling physiologically-based pharmacokinetics & physiologically based biopharmaceutics. Maaen J Med Sci. 2025;4(3).","DOI":"10.55810\/2789-9136.1078"},{"key":"1668_CR73","unstructured":"US Food and Drug Administration. Physiologically based pharmacokinetic analyses: format and content: guidance for industry. Silver Spring (MD): US Food and Drug Administration; 2018."},{"key":"1668_CR74","unstructured":"European Medicines Agency. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. EMA\/CHMP\/458101\/2016. Amsterdam: European Medicines Agency; 2018."},{"issue":"Suppl. 1","key":"1668_CR75","first-page":"S115","volume":"62","author":"L Zheng","year":"2022","unstructured":"Zheng L, Yang H, Dallmann A. Antidepressants and antipsychotics in human pregnancy: transfer across the placenta and opportunities for modeling studies. J Clin Pharmacol. 2022;62(Suppl. 1):S115\u201328.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1668_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70141","volume":"15","author":"JWT Yates","year":"2026","unstructured":"Yates JWT, Zientek M, Taskar KS, Lin W, Heimbach T, Willmann S, et al. Physiologically-based pharmacokinetic modeling to support pediatric clinical development: an IQ Working Group Perspective on the current status and challenges. CPT Pharmacometrics Syst Pharmacol. 2026;15(1):e70141.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1668_CR77","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3389\/fpsyt.2020.00717","volume":"11","author":"K Boaden","year":"2020","unstructured":"Boaden K, Tomlinson A, Cortese S, Cipriani A. Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment. Front Psychiatry. 2020;11:717.","journal-title":"Front Psychiatry."},{"issue":"4","key":"1668_CR78","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.3390\/ijerph20043473","volume":"20","author":"D Deepika","year":"2023","unstructured":"Deepika D, Kumar V. The role of \u201cphysiologically based pharmacokinetic model (PBPK)\u201d new approach methodology (NAM) in pharmaceuticals and environmental chemical risk assessment. Int J Environ Res Public Health. 2023;20(4):3473.","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"1668_CR79","volume":"13","author":"N Jahan","year":"2021","unstructured":"Jahan N, Went TR, Sultan W, Sapkota A, Khurshid H, Qureshi IA, et al. Untreated depression during pregnancy and its effect on pregnancy outcomes: a systematic review. Cureus. 2021;13(8):e17251.","journal-title":"Cureus."},{"key":"1668_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.687978","volume":"9","author":"P Coppola","year":"2021","unstructured":"Coppola P, Kerwash E, Cole S. Physiologically based pharmacokinetics model in pregnancy: a regulatory perspective on model evaluation. Front Pediatr. 2021;9:687978.","journal-title":"Front Pediatr"},{"key":"1668_CR81","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-2003-39983","volume":"36","author":"MJDA M\u00fcller","year":"2003","unstructured":"M\u00fcller MJDA, Fric M, Gaertner I, Grasm\u00e4der K, H\u00e4rtter S, Hermann E, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36:98\u2013104.","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"1668_CR82","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-0029-1220890","volume":"42","author":"C Waldschmitt","year":"2009","unstructured":"Waldschmitt C, Vogel F, Pfuhlmann B, Hiemke C. Duloxetine serum concentrations and clinical effects: data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry. 2009;42(5):189\u201393.","journal-title":"Pharmacopsychiatry"},{"key":"1668_CR83","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s004060050024","volume":"248","author":"UBR Hegerl","year":"1998","unstructured":"Hegerl UBR, Gallinat J, Kuss HJ, Ackenheil M, M\u00f6ller HJ. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96\u2013103.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"1668_CR84","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/01.jcp.0000227355.54074.14","volume":"26","author":"OQ Yin","year":"2006","unstructured":"Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol. 2006;26(4):367\u201372.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"1668_CR85","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00213-023-06484-7","volume":"241","author":"XM Lense","year":"2024","unstructured":"Lense XM, Hiemke C, Funk CSM, Havemann-Reinecke U, Hefner G, Menke A, et al. Venlafaxine\u2019s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis. Psychopharmacology. 2024;241(2):275\u201389.","journal-title":"Psychopharmacology"},{"issue":"2","key":"1668_CR86","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/FTD.0000000000001142","volume":"46","author":"XMSM Hart","year":"2024","unstructured":"Hart XMSM, Defert J, Uchida H, Gr\u00fcnder G. Update lessons from PET imaging part II: a systematic critical review on therapeutic plasma concentrations of antidepressants. Ther Drug Monit. 2024;46(2):155\u201369.","journal-title":"Ther Drug Monit"},{"issue":"1\u201302","key":"1668_CR87","first-page":"9","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1\u201302):9\u201362.","journal-title":"Pharmacopsychiatry"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01668-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:02:18Z","timestamp":1786467738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01668-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1668"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01668-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rebecca Leyla Huber and Oliver Scherf-Clavel have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors\u00a0contributed equally to the conception of this review. RLH performed the literature search and data analysis, and\u00a0wrote the first draft of the manuscript. OSC\u00a0supervised the work,\u00a0reviewed and edited\u00a0the manuscript,\u00a0and provided expertise on the results.\u00a0All authors have read and approved the final version of the manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}